KLOW Legal

Field guide // the literature

KLOW peptide references

Every quantitative claim on this site maps to a numbered source below. Component-level studies and the 2024-2026 record, with DOIs and PubMed links.

Back to the researchThe four-peptide blend

How to read this list

Every source below is component-level — a study of KPV, GHK-Cu, BPC-157 or thymosin beta-4 on its own — because no controlled study of the four-peptide KLOW blend exists. The numbers match the inline citation markers used across this site's recent KLOW research, KLOW side effects and reported KLOW effects pages. Where a claim is attributed to the blend rather than a single arm, the text says so explicitly and points to this absence.

  1. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
  2. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. ↗
  4. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗
  6. Lee S, Lee SM, Lee SH, Choi WK, Park SJ, Kim DY, et al. In situ photo-crosslinkable hyaluronic acid-based hydrogel embedded with GHK peptide nanofibers for bioactive wound healing. Acta Biomaterialia. 2023. ↗
  7. Dymek M, Olechowska K, Hac-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. ↗
  8. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Sun Q, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024;15:1442876. ↗
  11. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. ↗
  12. World Anti-Doping Agency. The Prohibited List — S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics (thymosin beta-4 / TB-500 prohibited at all times). WADA. ↗
  13. Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025. ↗
  14. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  15. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗